Drug data last refreshed 47m ago · AI intelligence enriched 2mo ago
PHOTREXA VISCOUS IN DEXTRAN 20% is a riboflavin 5-phosphate ophthalmic solution approved by the FDA in April 2016 for corneal cross-linking procedures. It is used in conjunction with UV-A light exposure to strengthen corneal collagen and halt progressive keratoconus and corneal ectasia. The product works by enabling riboflavin-mediated photochemical cross-linking of corneal collagen fibers when activated by UVA light.
Product is in peak lifecycle stage with moderate competitive pressure (30%), indicating stable team size and established commercial infrastructure.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PHOTREXA VISCOUS offers exposure to specialized ophthalmology and procedural medicine with a niche but growing patient population. Career progression opportunities exist in peak-stage commercial optimization, though limited trial activity indicates focus on market consolidation rather than pipeline expansion.
Worked on PHOTREXA VISCOUS IN DEXTRAN 20% at Glaukos? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.